RxDoctor Payments DataLook up a doctor →

Whitney Stevens

Gerontology · Slidell, LANPI 1366021149

Payments from drug & device makers

$10,240in general payments, 2019–2025

Across 330 payments — averaging $31.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$2K
  • Johnson & Johnson$899
  • Novartis$696
  • E.r. Squibb & Sons, L.L.C.$417
  • AstraZeneca$412
  • Merck$376
  • plus $5K from 48 others

What the payments were for

  • Consulting fees$1,15511%
  • Travel & lodging$2242%
  • Food & beverage$7,60774%
  • Education$9549%
  • Other$2993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,240 in reported general payments places this provider in the 95th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana

Medicare billing

Part B allowed, 2024
$40,101
Medicare patients
112
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate86$270,088
Lenalidomide18$266,788
ErleadaApalutamide11$190,942
EliquisApixaban156$141,679
PromactaEltrombopag Olamine13$99,257
XareltoRivaroxaban63$55,806
Imatinib Mesylate32$13,180
Tamoxifen Citrate72$1,691
Dronabinol12$1,596
Ondansetron Hcl138$1,210
Dexamethasone34$1,152
Enoxaparin Sodium11$1,136
Anastrozole58$1,117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$874
Potassium Chloride85$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$72$270,08886 claims
Johnson & JohnsonErleada, Xarelto$899$246,74874 claims
PfizerEliquis$234$141,679156 claims
NovartisPromacta$696$99,25713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 gerontology providers in Louisiana.

Other gerontology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →